Treatment of Type 1 Diabetes: Transplantation of Insulin Producing Cells
A special issue of Diabetology (ISSN 2673-4540).
Deadline for manuscript submissions: 20 May 2026 | Viewed by 66
Special Issue Editor
Special Issue Information
Dear Colleagues,
Transplantation of insulin-producing cells can be a promising therapy for patients with severe type 1 diabetes with unstable control of blood glucose level in spite of intensive insulin treatment. It is an ideal therapy from the point of view of recovering sufficient internal insulin provision for controlling blood glucose level. The guest editor invites many basic and clinical studies about transplantation of insulin-producing cells, including human islets, insulin-producing cells derived from multipotent stem cells, islets obtained from large animals such as pigs, or mesenchymal stem cells for this Special Issue. Islet transplantation has contributed to the improvement of quality of life of many severe type 1 diabetic patients for over 20 years. Regarding multipotent stem cells, some clinical trials of transplantation of insulin-producing cells are performed. Furthermore, recent clinical trials of organ xenotransplantation using gene-edited pigs are promoted and show better results. It is considered that porcine islet xenotransplantation might be feasible in the near future. In this Special Issue, original articles, review articles, and case reports are widely accepted.
Dr. Naoaki Sakata
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diabetology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- islet transplantation
- iPS cells
- ES cells
- mesenchymal stem cells
- islet xenotransplantation
- immunosuppressants
- animal model
- clinical trial
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
